These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33268268)

  • 1. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
    Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
    HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    de Carvalho LFA; Gryspeerdt F; Rashidian N; Van Hove K; Maertens L; Ribeiro S; Hoorens A; Berrevoet F
    BMC Surg; 2023 Sep; 23(1):296. PubMed ID: 37775737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
    Zhou Y; Liao S; You J; Wu H
    Updates Surg; 2022 Feb; 74(1):43-53. PubMed ID: 34021484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
    Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
    Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
    Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
    Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.
    Alva-Ruiz R; Yohanathan L; Yonkus JA; Abdelrahman AM; Gregory LA; Halfdanarson TR; Mahipal A; McWilliams RR; Ma WW; Hallemeier CL; Graham RP; Grotz TE; Smoot RL; Cleary SP; Nagorney DM; Kendrick ML; Truty MJ
    Ann Surg Oncol; 2022 Mar; 29(3):1579-1591. PubMed ID: 34724125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
    Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
    Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
    Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
    Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
    Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
    World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.